On September 3, 2026, Milestone Pharmaceuticals Inc. announced that China’s National Medical Products Administration approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia in adults. This regulatory approval marks the first authorization of etripamil outside the United States and triggers a $2.0 million milestone payment to Milestone under its exclusive license agreement with Everest Medicines, which leads commercialization in Greater China. The company remains eligible for up to $98.0 million in additional milestones and tiered royalties of up to 18% on future sales. Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines.

Milestone Pharmaceuticals Inc. reported financial results for the second quarter ended June 30, 2026, revealing a net loss of $28.6 million, or $0.21 per share, compared to a $13.0 million loss in the prior year period. Product revenues reached $0.6 million, driven by the commercial launch of CARDAMYST (etripamil) nasal spray for PSVT, which saw over 1,500 scripts filled and coverage expand to approximately 50% of commercially insured lives in the U.S. The company holds $170.6 million in cash and short-term investments, providing a runway into the second half of 2027. Additionally, Milestone announced that its Phase 3 ReVeRA-301 trial for AFib-RVR has activated clinical sites and begun patient enrollment. Milestone Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative cardiovascular medicines.

At its annual meeting on June 10, 2026, Milestone Pharmaceuticals Inc. shareholders approved an amendment to the 2019 Equity Incentive Plan, increasing authorized ordinary shares for issuance by 6,800,000. Shareholders also elected seven directors, including Joseph Oliveto, Stuart M. Duty, Seth H.Z. Fischer, Lisa M. Giles, Joseph C. Papa, Andrew R. Saik, and Michael Tomsicek, to serve until the 2027 annual meeting. Additionally, the meeting resulted in the ratification of PricewaterhouseCoopers LLP as the company's auditor and a non-binding advisory vote on executive compensation. Milestone Pharmaceuticals Inc. is a pharmaceutical company.